Down 74% Over the Past Year, Is Moderna Stock a Buy?

In the short term, Moderna (NASDAQ: MRNA) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I think the stock might stay low for quite a while. But, if its pipeline of new products comes into play, including work on new treatments in oncology, then Moderna stock -- down 74% in the year ending July 21 -- might have some great long-term potential. In 2022, Moderna had over $19 billion in revenue. In 2024, that revenue had fallen to $3.24 billion. So where's the appeal? Very recently, the company received approval for its COVID-19 for vaccine for at-risk children who are 6 months or older. This does open a new demographic for the company, but I have to question whether that will bring the company back to $19 billion in annual revenue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool